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Abstract
Background: Hot flushes are the most frequent climacteric symptom and a major cause of suffering
among menopausal women. The condition negatively influences many aspects of women's lives. To date,
conventional hormone replacement therapy (HRT) is considered the most effective treatment for hot
flushes. However, HRT is associated with a host of negative side effects. Complementary and alternative
medical (CAM) approaches have been employed to relieve symptoms and to avoid these side effects.
Acupuncture is one of the most strongly preferred CAM treatments for many diseases, causing few serious
adverse effects, and is frequently used in Korea.
We aim to evaluate the effectiveness of Traditional Korean Acupuncture (TKA) in conjunction with usual
care, compared to usual care alone, on hot flushes in perimenopausal and postmenopausal women in
Korea.
Methods:  This study consists of a multi-center randomized controlled trial with 2 parallel arms.
Participants included in the study will meet the following criteria: 1) a documented daily average hot flush
score ≥ 10 for one week prior to the screening visit 2) not taking HRT and other pharmaceutical therapies
which might affect hot flushes or other vasomotor symptoms.
While maintaining usual care, the treatment group will receive acupuncture 3 times a week, for a total of
12 sessions over 4 weeks. The control group will receive usual care alone during the same period. Post-
treatment follow-up will be performed one month after completing 12 sessions of acupuncture.
Discussion: This trial will provide evidence for the effectiveness of acupuncture as a treatment for hot
flushes. The primary endpoint in both groups is a change in hot flush score from baseline to week 4 and/
or week 8. As the secondary endpoint, we will employ the Menopause Rating Scale (MRS), a health-related
quality of life questionnaire. Further analysis will examine the frequency, severity and difference in
symptoms for daytime vs. nighttime hot flushes, sub-domain analysis of MRS, and participants' expectations
of acupuncture treatment.
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Background
Hot flushes are the most frequent climacteric symptom
and a major cause of suffering in menopausal women
[1,2]. Diminished overall quality of life, social distress
and emotional embarrassment are also frequent com-
plaints due to menopause-associated hot flushes [3].
The prevalence of hot flushes varies according to ethnicity,
region and cultural characteristics [4,5]. Most women
experience hot flushes for 6 months to 2 years [4]. For
many women, most menopause-related vasomotor symp-
toms including hot flushes tend to resolve spontaneously
within a few months [6]. About 29% of 60-year-old
women, however, report persistent hot flushes [6].
It is well known that the most effective treatment for hot
flushes is hormone replacement therapy (HRT) [7].
Recent research performed by the Women's Health Initia-
tive and the Million Women Study, however, suggests
HRT may increase the risk of coronary heart disease [8],
stroke [9], breast and endometrial cancer [10,11]. These
findings regarding the adverse effects and potential risks
of HRT have led to an expanded interest in non-hormonal
therapies for managing hot flushes [12]. However, there
are only limited data to support their use, and some
adverse effects may be linked to certain types of non-hor-
monal therapies [13]. Herbs and phyto-estrogens have
also been used in the clinic to alleviate menopausal symp-
toms, and many individual trials reported positive results
for these therapies in reducing hot flushes. Such method-
ologies still require further research in terms of efficacy
and long-term safety [14,15].
Acupuncture has been used worldwide to treat various
conditions and diseases. In the context of clinical practice
in Korea, acupuncture is one of the most frequently deliv-
ered modalities of medical treatment. In 1997, an NIH
conference reached the consensus that acupuncture could
be employed as a useful part of treatments in several clin-
ical situations [16]. Since then, acupuncture has been
increasingly adapted to treat a wide range of conditions
and numerous related research efforts are currently being
conducted around the globe. According to recent studies
on the safety of acupuncture, it represents one of the safer
forms of medical intervention with a low rate of adverse
effects if performed by well-trained practitioners [17-19].
For treatment of hot flushes, acupuncture causes only
minor side effects as opposed to conservative therapies,
including HRT and non-hormonal agents, which cause
more drastic adverse effects [8-11,13,17-19].
To date, acupuncture treatments have been increasingly
utilized in several clinical trials for hot flushes due to
menopause, breast cancer, and prostate cancer in males.
Two randomized controlled trials (RCTs) (n = 24, n = 30)
were carried out comparing electroacupuncture to sham
acupuncture. These trials showed no significant differ-
ences between the two groups, but they did show consid-
erable symptom reductions within each group [20,21].
One relatively large RCT (n = 103) showed no significant
differences between real acupuncture and sham acupunc-
ture [22], but a small RCT (n = 29) found that there was a
significant difference between active acupuncture and pla-
cebo needles in terms of the severity, but not the fre-
quency, of nocturnal hot flushes [23].
Notably, the first RCT (n = 52) using acupuncture for hot
flushes in Korea was conducted with postmenopausal
women. Comparing manual acupuncture to minimal acu-
puncture at the same points, the study showed no signifi-
cant differences between the two groups, but also
demonstrated significant symptom alleviation within
both groups [24]. An unpublished study (n = 54) was car-
ried out by the same group, comparing active acupuncture
to placebo acupuncture, penetrating non-acupoints with-
out reaching de-qi sensation on perimenopausal and
postmenopausal women. The study failed to show signif-
icant differences between two groups, but showed a
decrease in symptoms within groups. In breast cancer
patients, one placebo-controlled RCT (n = 72) showed
reduced hot flush frequency within the active acupuncture
group, but no significant differences were found when
comparing these subjects to Streightberger sham needle
groups [25]. In prostate cancer patients that underwent
castrational treatment, a small study (n = 31) employing
two styles of acupuncture, electroacupuncture and tradi-
tional acupuncture, found that both treatment methodol-
ogies significantly lowered the number of hot flushes, as
well as the distress from hot flushes (by 78% and 73%,
respectively) [26].
As stated above, most research on the efficacy of acupunc-
ture in the treatment of hot flushes failed to show any sig-
nificant advantage of this technique as compared to the
use of placebo needles. However, there were also some
promising results which might support positive clinical
implications; many studies found at least a 50% decrease
of hot flushes within group after intervention. In one
review regarding hot flushes, the authors reported a hot
flush score reduction of greater than 50% by certain
agents should be regarded as having greater effects than
placebo effects [27]. Importantly, there is currently no sat-
isfactory placebo acupuncture which is proven to be com-
pletely inert, so comparing acupuncture with placebo
needles might underestimate the total effects of acupunc-
ture [28]. In this study, we will investigate the comprehen-
sive effects of acupuncture treatment in conjunction with
usual care, as compared to usual care alone, avoiding the
issues associated with placebo needling.Trials 2008, 9:70 http://www.trialsjournal.com/content/9/1/70
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Methods
Inclusion criteria
Participants will be recruited from four centers (Seoul,
Ilsan, Jecheon and Busan) by the use of local newspaper
advertisements and posted notices at clinic cites. Partici-
pants include perimenopausal or postmenopausal
women from 45 to 60 years old, who have average daily
hot flush scores > 10 for one week prior to the screening
visit (Hot flush scores: daily frequency × severity [0: none,
1: mild, 2: moderate, 3: severe, 4: very severe]). Serum
TSH and free T4 levels will be tested to determine normal
thyroid function.
We defined the term "perimenopausal" as menstrual
irregularity or amenorrhea of 3–11 months [29,30], and
the term "postmenopausal" as (1) 12 months of sponta-
neous amenorrhea or (2) 6 months of spontaneous amen-
orrhea with serum FSH levels > 40 mIU/ml or (3) 6 weeks
postsurgical bilateral oophorectomy with or without hys-
terectomy or (4) hysterectomy with at least one intact
ovary [31,32]. Despite the recommendation of the korpi-
lampi workshop(1986) not to combine subjects undergo-
ing natural menopause with those experiencing surgical
menopause for analytic purposes [33], related studies
which compare the risk of menopausal symptoms by the
type of menopause are sparse and have shown conflicting
results [34-36]. We thus included women undergoing
menopause due to both natural causes and surgery.
Instead, we will not only analyze data in a pooled popu-
lation, but also perform a sub-analysis examining data
separately for those with natural or surgical menopause.
Exclusion criteria
Participants will be excluded when they are suffering seri-
ous medical conditions, such as uncontrolled hyperten-
sion, diabetes mellitus requiring insulin injection, any
type of thyroid dysfunction, past or current malignant
tumor, severe dyslipidemia, other infectious diseases or
systemic diseases insufficient for acupuncture treatment.
Ineligible participants will also include those who used
any hormones, antidepressants, gabapentin, selective
serotonin reuptake inhibitors (SSRI) or sedatives. In the
case of previous or current use of HRT, adequate wash-out
periods will be dictated according to the type of HRT (i.e.
oral administration, transdermal patch or injection).
Over the counter (OTC) drugs will be allowed for manag-
ing episodic colds, headaches and dyspepsia, etc. Some
supplements including evening promise oil, phytoestro-
gens, omega-3 fatty acids, calcium and vitamins will also
be permitted; however, participants will be gently advised
to reduce the dose, stop taking the supplement, or at least
refrain from adding another supplement to their regimen.
Some OTC drugs containing black cohosh and human
placenta extracts will not be allowed since there are con-
cerns that those herbs might directly affect hot flushes and
other vasomotor symptoms, in certain constitutions,
according to Traditional Korean Medicine (TKM) theory.
We will investigate the drugs taken by each participant at
every visit and request that study participants notify us of
any addition to their medication/supplement regimen.
Any additional acupuncture treatment, herb prescription,
or therapeutic intervention by another TKM doctor will
not be allowed during the study. For the purpose of ana-
lyzing daytime and nighttime hot flushes separately, we
will exclude participants who work at night. See eligibility
criteria in table 1.
Interventions
TKA regimens designed according to TKM clinical experts
will be used in this trial for alleviating hot flushes and vas-
omotor symptoms by balancing yin and yang in the par-
ticipant. These regimens were also used in two previous
studies [25], one of which is unpublished and mentioned
above. The TKM doctors who conduct the treatments have
practiced for at least 3 years in the clinic; they belong to
each clinical center spread among different provinces in
South Korea.
Participants will be randomly assigned to either the acu-
puncture treatment plus usual care group or the usual care
alone group. The acupuncture treatment plus usual care
group will receive acupuncture 3 times/week, for a total of
12 sessions. Six acupuncture points (ST36, SP6, LI4, PC6,
HT7, HT8) will be inserted bilaterally in the four periph-
eral extremes and one point (CV4) will be inserted unilat-
erally in the lower abdominal region. TKM doctors will
manually manipulate the acupuncture needles with de-qi
sensation and maintain the needles for 20 minutes with
intermittent manual stimulation. Infrared irradiation will
be used to warm the lower abdomen during the 20 min-
utes of acupuncture treatment, as it is performed in con-
junction with acupuncture, generally.
TKM doctors will use sterile, disposable needles with a
length of 40 mm and a diameter of 0.25 mm (Dongbang
Acupuncture Inc, Korea). They will be inserted to a depth
of 3–15 mm, according to the points selected.
Participants who will be allocated to usual care alone
group will receive no acupuncture treatments throughout
the 4 weeks. They will record their hot flush symptoms in
a daily diary. After four weeks, if participants elect to try
the acupuncture treatment, the same treatment will be
provided.
Study outcome
The primary outcome measure is the hot flush score, pro-
duced by multiplying severity and frequency of hotTrials 2008, 9:70 http://www.trialsjournal.com/content/9/1/70
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flushes during a 24-hour period in a daily diary, which
demonstrates validity and reliability in measuring hot
flush activities [27]. Participants will be asked to record
the number and severity of daily hot flushes during the
entirety of the study period. Participants in both groups
will also be routinely encouraged to fill out the diary by
periodic short message service (SMS) and phone-call
reminder both in order to avoid the selective loss to fol-
low up, that is, selection bias and to prevent the indolence
of writing daily diaries which are associated with partici-
pant knowledge-related bias in this unblinded trial. We
will employ the slightly modified severity rating scale
(0:none, 1:mild, 2:moderate, 3:severe, 4:very severe) sug-
gested in the studies of Sloan et al. [27].
We will examine the reduction in hot flushes over a 24-
hour period, as well as daytime and nighttime separately
for sub-analytic purpose to check whether acupuncture
has different effects on daytime versus nighttime hot
flushes.
The secondary outcome measure is the Menopause Rating
Scale (MRS) to assess other vasomotor symptoms. MRS is
a highly qualified self-administered questionnaire for
assessment of menopausal symptoms [37]. It contains 11
questions divided into 3 categories: psychological,
somatic and urogenital.
We will also estimate the expectations of participants by
using the credibility and expectancy questionnaire, aim-
ing to determine whether expectations make a difference
to outcome [38,39]. In order to assess expectations with-
out potential influences by participants' knowledge of
allocation results, a questionnaire will be administered to
eligible women before notification of assignments. Data
collection schedule is detailed in table 2.
In case of an unblinded trial, the rater(or assessor) knowl-
edge of treatment assignment could modify the outcome
assessment [40]. We employed only patient- reported and
self-administered outcomes with concerns of potential
rater bias in outcome assessment. However, related bias
due to the unblindness might still occur despite all of
efforts to prevent them. It should be recognized as an una-
voidable limitation of this study design.
Randomization
Ultimately, 180 participants will be randomized to the
acupuncture treatment plus usual care group or usual care
alone group and divided into four centers (see Figure 1).
Each center will recruit a total of 45 participants, with 30
assigned to the acupuncture plus usual care group and 15
to the usual care alone group. A block size of 3 is used to
assign 2 for acupuncture treatment plus usual care group
and 1 for usual care alone group. Separate randomization
table will be provided for each center.
Ethics
Oral and written consent will be obtained from each par-
ticipant. This study was approved by the institutional
Table 1: Eligibility Criteria
Inclusion criteria
45–60 years old
Perimenopausal women (menstrual irregularity or amenorrhea of 3 – 11 months)
Postmenopausal women:
- 12 months of spontaneous amenorrhea
- 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml
- 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy
- hysterectomy with at least one intact ovary
Average daily hot flash scores > 10 for one week prior to screening visit
Exclusion criteria
Poorly controlled hypertension
Diabetes mellitus needed to be controlled by insulin injection
History of past or current malignant tumor
Any type of thyroid dysfunction
Severe dyslipidemia
Other infectious diseases or systemic diseases inadequate for acupuncture treatment
Other serious medical conditions
Use of HRT, antidepressants, gabapentin, SSRI's, sedatives
Use of unidentified herb prescriptions or herbs the investigator considers to affect hot flushes
Over-the-counter drugs which contain black cohosh or human placenta.
Working at nightTrials 2008, 9:70 http://www.trialsjournal.com/content/9/1/70
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review boards at the Dongguk International Hospital,
East-West Neo Medical Center of Kyung Hee University,
Semyung University Hospital and Dong Eui Medical
Center.
Statistical methods and sample size
Analyses will be performed for two populations: 1) an
intention-to-treat population consisting of all rand-
omized participants with at least one measurable out-
come report following acupuncture treatment (missing
data will be replaced with last observation values); 2) a
per protocol population including only participants with-
out major protocol deviations. All data will be analyzed
descriptively. All main analyses will be based on the inten-
tion-to-treat population. For primary and secondary out-
come measures, the mean differences from baseline
values to the end of treatment will be compared using
two-sample t-test or Wilcoxon rank sum test. A trend test
will also be performed using repeated measures analysis
of variance. We adjusted for possible confounders using
criteria of statistical significance.
All adverse events reported during the study will be
included in the charts; then incidences of adverse events
will be calculated. The percentage of the subjects with
adverse events in each group will be calculated and com-
pared with the chi-squared test or Fisher's exact test value.
Statistical analyses will be performed using the SAS statis-
tical package program (ver. 9.1.3) and the level of signifi-
cance will be established at α < 0.05. In calculating the
sample size, we assumed a power of 90% and α value of
5%, in order to detect a hot flush score difference of 15.34
with a standard deviation of 26.5 drawn by two previous
studies in Korea [24,41]. Therefore the acupuncture plus
usual care and usual care alone group (2:1 allocation) will
include 120 and 60 participants, respectively, allowing for
a 20% withdrawal rate. This implies a sample size of 45
for each center, with 30 participants per acupuncture
treatment plus usual care group and 15 per usual care
alone group.
Data handling
Investigators will enter the information required by the
protocol into the Case Report Forms (CRFs). Non-obvi-
ous errors or omissions are entered on data query forms,
which will be returned to the investigational site for reso-
lution.
The data from all centres are pooled and summarized with
respect to demographic baseline characteristics, effective-
ness and safety observations.
Data and safety monitoring
Regular monitoring will be conducted for quality control.
Also, investigators can be convened to discuss practical
issues that may be encountered such as adjusting recruit-
ment capacity within each center, dealing with serious
adverse events, revising the protocol, as well as certain
important issues that may be raised by investigators and
participants.
The assessment of safety will be based mainly on the fre-
quency of adverse events, which includes all serious
adverse events. Information regarding adverse events will
be summarized by presenting the number and percentage
of participants experiencing any adverse event, with the
information also divided by body system. Any other infor-
mation collected (e.g. severity or relatedness to acupunc-
ture treatments) will be listed as appropriate.
Abbreviations
HRT: Hormone Replacement Therapy; CAM: Comple-
mentary and Alternative Medicine; TKA: Traditional
Table 2: Data Collection Schedule
Measures Screening Baseline Randomization End Follow-up
Week number -1 0 1 2 3 4 6 8
Sociodemographic characteristics O
Hot flush diary O O O O O O O O
Credibility and Expectancy questionnaire O
MRS OO O O O
Medical history O
Physical activity O
Smoking/Alcohol O
Pharmaceutical therapies (OTC and prescribed drugs) O O O O O O O
Herb medications O O O O O O O
Adverse effects OOO O
FSH, Estradiol O
TSH, Free T4 OTrials 2008, 9:70 http://www.trialsjournal.com/content/9/1/70
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Flow diagram of study design Figure 1
Flow diagram of study design.
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Korean Acupuncture; MRS: Menopause Rating Scale; NIH:
National Institutes of Health; RCT: Randomized Control-
led Trial; TSH: Thyroid Stimulating Hormone; FSH: Folli-
cle Stimulating Hormone; SSRI: Selective Serotonin
Reuptake Inhibitor; OTC: Over The Counter; TKM: Tradi-
tional Korean Medicine; SMS: Short Message Service; CRF:
Case Report Form.
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